Courtney Fitzhugh received her B.S. magna cum laude from the University of California, Los Angeles in 1996, and her M.D. from the University of California, San Francisco in 2001. She is a member of the American Society of Hematology. Dr. Fitzhugh is exploring new avenues of hematopoietic stem cell (HSC) transplantation for sickle cell disease (SCD), while also studying the currently underexplored cardiovascular complications arising due to this genetic blood disorder. Dr. Fitzhugh is also conducting a half-matched protocol to increase the number of people eligible for HSC transplantation.

The current procedure requires a fully HLA-matched sibling donor, and less than 20% of SCD patients would qualify. Dr. Fitzhugh is examining why SCD patients develop heart disease, and what can be done to prevent or possibly even reverse heart-related complications in this population. Through these joint avenues of research, Dr. Fitzhugh’s group is finding new avenues to help people with SCD live longer and healthier lives. Dr. Fitzhugh is also interested in learning more about death due to this disease.

Representative Publications:

Losartan for the nephropathy of sickle cell anemia: A phase-2, multicenter trial

Allogeneic hematopoietic stem-cell transplantation for sickle cell disease

Relationship between Mixed Donor-Recipient Chimerism and Disease Recurrence Following Hematopoietic Cell Transplantation for Sickle Cell Disease

Curative approaches for sickle cell disease: A review of allogeneic and autologous strategies

Measurements of red cell deformability and hydration reflect HbF and HbA2 in blood from patients with sickle cell anemia

Severe cardiac iron toxicity in two adults with sickle cell disease

Do the Eyes Reveal More Than Scleral Icterus in Sickle Cell Disease?

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder